The first developed RAD51-based HRD test, the REcombination CAPacity (RECAP) test, has shown a high sensitivity in identifying breast and ovarian tumors with PVs in BRCA1/2 or BRCA1 promoter hypermethylation [23, 26, 28–31]. This evidence concerns the gene BRCA1 and ovarian neoplasm.